Da32 Life Science Tech Acquisition Corp Cl A (DALS)
Da32 Life Science Tech Acquisition Corp Cl A (DALS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 304 | 699 | 861 | 1,101 | 1,605 |
| TOTAL | $491 | $929 | $1,201 | $1,539 | $2,155 |
| Non-Current Assets | |||||
| Investments And Advances | 204,493 | 202,927 | 201,205 | 200,200 | 200,055 |
| TOTAL | $204,493 | $202,927 | $201,205 | $200,200 | $200,055 |
| Total Assets | $204,984 | $203,856 | $202,406 | $201,739 | $202,210 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 0 | 1 | 1 | 0 | 32 |
| Accrued Expenses | 432 | 420 | 327 | 261 | 226 |
| TOTAL | $1,353 | $1,050 | $584 | $303 | $307 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 208,740 | 207,542 | 206,221 | 205,600 | 205,600 |
| TOTAL | $208,740 | $207,542 | $206,221 | $205,600 | $205,600 |
| Total Liabilities | $210,093 | $208,592 | $206,805 | $205,903 | $205,907 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 25,650 | 25,650 | 25,650 | 25,650 | 25,650 |
| Common Shares | 1 | 1 | 1 | 1 | 1 |
| Retained earnings | -5,109 | -4,736 | -4,400 | -4,165 | -3,698 |
| TOTAL | $-5,109 | $-4,736 | $-4,400 | $-4,164 | $-3,697 |
| Total Liabilities And Equity | $204,984 | $203,856 | $202,406 | $201,739 | $202,210 |